Navigation Links
Cambrex Reports Third Quarter 2008 Results
Date:11/4/2008

same period last year. The decrease is a result of corporate headquarters restructuring activities and expense reductions within the Company's manufacturing facilities, partially offset by the negative impact of foreign currency.

Research and Development ("R&D") Expenses for the third quarter 2008 were $1.8 million compared to $3.1 million in the third quarter 2007. The decrease is primarily due to the Company's decision in 2007 to consolidate its New Jersey technical center into the Company's Iowa facility in order to create increased operating efficiencies. Cambrex also utilized certain R&D personnel on custom development projects resulting in these costs being classified as Cost of Goods Sold.

Strategic Alternative and Restructuring Costs totaling $1.2 million in the third quarter 2008 include $0.3 million of costs related to the consolidation of operations at the New Jersey technical center into the Iowa facility, and $0.9 million of expense related to severance, change-in-control liabilities, and the ongoing project to streamline the Company's legal entity structure in order to lower operating costs and increase tax efficiency.

Net Interest Expense in the third quarter 2008 was $1.0 million compared to $1.1 million in the third quarter 2007. The Company capitalized interest of $0.5 million on long-term projects in the third quarter of 2008.

The effective tax rate for the third quarter 2008 was 9.8% and the Provision for Income Taxes totaled $0.3 million. Favorable resolution of certain tax issues resulted in a benefit to tax expenses of $1.5 million during the third quarter 2008. The Company's effective tax rates have been and are expected to remain highly sensitive to the geographic mix of income due to the Company's inability to recognize tax benefits for U.S. GAAP purposes in certain jurisdictions where there has been a recent history of losses, primarily the U.S.

Third Quarter 2008 Capital Expenditures and Depreciation '/>"/>

SOURCE Cambrex Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related biology technology :

1. Cambrex Presentation at the JPMorgan Healthcare Conference to be Webcast
2. Cambrex to Announce Fourth Quarter and Full Year 2007 Financial Results on February 14, 2008
3. Cambrex Appoints Steven M. Klosk as President and CEO
4. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
5. QMed, Inc. Reports July Medicare SNP Enrollments
6. Phlo Affiliate Reports Expanded Coverage to Oregon Border
7. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
8. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
9. Carrington Reports Second Quarter 2007 Results
10. Avitar Reports Third Quarter Financial Results for Fiscal 2007
11. Response Genetics Reports Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... have succeeded in measuring vibrational motion of a single ... how vibration of a single molecule differs from the ... was performed at the University of California, Irvine, where ... works as a visiting fellow under professor Vartkess A. ... team was lead by Professor Eric O. Potma. The ...
(Date:8/20/2014)... Francisco, CA (PRWEB) August 20, 2014 ... Conference is being held on October 29-30 in ... perspectives from industry, academic and government researchers and clinicians ... in the space. , In the twelve years ... one hundred therapies have been introduced with pharmacogenetic information ...
(Date:8/20/2014)... GraphDB™ 6.0 from ... to the enterprise replication cluster, faster loading speeds, ... and Elasticsearch. This release happens to coincide with ... – GraphDB™ was formerly known as OWLIM. ... mature enterprise resilient RDF triplestore will also benefit ...
(Date:8/19/2014)... 19, 2014 Cellgen Diagnostics ... $200,000 to fund a corporate lab for its ... This development is a critical component in the ... to the implementation of personalized medicine – a ... medicine. , Indiegogo contributions will support Cellgen’s intent ...
Breaking Biology Technology:Seeing a molecule breathe 26th Annual Personalized and Precision Medicine Conference Bringing Together Thought Leaders to Discuss Clinical Implementation, Dx Reimbursement, Big Data, and Sequencing 2Ontotext Improves Its RDF Triplestore, GraphDB™ 6.0: Enterprise Resilience, Faster Loading Speeds and Connectors to Full-Text Search Engines Top the List of Enhancements 2Ontotext Improves Its RDF Triplestore, GraphDB™ 6.0: Enterprise Resilience, Faster Loading Speeds and Connectors to Full-Text Search Engines Top the List of Enhancements 3Ontotext Improves Its RDF Triplestore, GraphDB™ 6.0: Enterprise Resilience, Faster Loading Speeds and Connectors to Full-Text Search Engines Top the List of Enhancements 4Cellgen Diagnostics Launches Indiegogo Crowdfunding Campaign for DNA Medical Testing Device 2Cellgen Diagnostics Launches Indiegogo Crowdfunding Campaign for DNA Medical Testing Device 3
... Calif., Oct. 5 Bionovo, Inc.,(Nasdaq: BNVI ), a ... in the areas of women,s health and cancer, today announced,that ... at the 4th,Annual BIO Investor Forum. The presentation will ... the Palace Hotel in San Francisco, CA. A live ...
... Cerimon,Pharmaceuticals, Inc., today announced Paul Sekhri, Cerimon,s ... 2007 BIO Investor Forum on,Thursday, October 11, 2007, ... in San,Francisco. The presentation will take place in ... Cerimon Pharmaceuticals, Inc. is a biopharmaceutical company ...
... Coalition for a,Competitive Pharmaceutical Market (CCPM) issued the ... announcement regarding its,"Generic Initiative for Value and Efficiency" ... grappling with,how to manage escalating prescription drug costs, ... focus on ways to enhance timely generic access.,Today,s ...
Cached Biology Technology:CCPM Issues Statement on FDA's GIVE Initiative 2
(Date:8/19/2014)... Aug. 19, 2014 To improve students, chances ... grades, the University of Houston (UH) implemented a ... students at risk for failure. , Through ... Board (THECB), the Department of Biology and Biochemistry ... students taking "General Biology" for non-majors and "Introductory ...
(Date:8/19/2014)... of the world, leprosy and tuberculosis live side-by-side. ... leprosy per year, with nearly all of them ... century-old vaccine Bacille Calmette-Guerin, or BCG, provides only ... a more potent vaccine is needed to combat ... stronger weapon against both diseases., In a study ...
(Date:8/19/2014)... Aug. 19, 2014 ) -- Scientists at the Houston ... up and transfer single cells using a pipette -- ... describe this engineering feat and preliminary test results in ... American Chemical Society . , "Studying single cells and ... biomedical research," said nanomedicine department. faculty member Lidong Qin, ...
Breaking Biology News(10 mins):University of Houson program earns kudos for improving grades, retaining students 2University of Houson program earns kudos for improving grades, retaining students 3New vaccine shows promise as stronger weapon against both tuberculosis and leprosy 2Moving single cells around -- accurately and cheaply 2
... century, scientists have struggled with plutonium contamination spreading further ... in humans and animals. It was known nanometer ... no one had been able to study its structure ... groundwater. Scientists at the U.S. Department of ...
... Spanish flu outbreak of 1918 killed between 30 and ... cause of death was acute respiratory distress syndrome (ARDS). ... body during which the lung becomes severely damaged. ARDS ... but also by chemical agents. These could be toxic ...
... the most common cause of episodic headache, and by ... visit. It affects some 15% of the population, including ... considerable burden on healthcare in both the developed and ... years, great strides have been made in discovering common ...
Cached Biology News:Scientists discover how nanocluster contaminants increase risk of spreading 2New strategies against bird flu 2Concentrating on different aspects of pain leads to breakthrough in migraine genetics 2
High affinity antibody reacting with S-100 ab heterodimer. Could be used for Western blotting application and immunoassay....
... (g/L):,Tryptone, 10 ,Yeast extract, 5 ,Sodium ... ,Ferric ammonium citrate, 0.5 ,IPTG, 0.03 ... soluble, autoclavable chromogenic substrate for -galactosidase. ... -galactosidase generates a black insoluble precipitate. ...
S-100 alpha/beta chain (8B10)...
SCCRO (S-17)...
Biology Products: